Dr. Dirk-Jan Opstelten

We are honored to introduce Dr. Opstelten, the Chairman of our Scientific Advisory Board. With a PhD in virology and over thirty years of experience in the pharmaceutical and biotechnology industries, Dr. Opstelten brings a wealth of knowledge and expertise to our team.

As Chairman, he actively participates in board meetings, offering invaluable advice on our programs and providing strategic leadership to achieve our objectives.

Dr. Opstelten has its own consultancy firm supporting biotech and pharmaceutical companies with medicinal product development and (interim) management of R&D organizations. In addition, he is board member of Desentum, a biotech company involved in the development of innovative vaccines for allergy. Previously, he has served in various pivotal roles, including Chief Scientific Officer at HAL Allergy Group and Program Director at Crucell (now J&J). His extensive background in leading R&D programs from early stage to market authorization and his contributions to scientific publications and patents underscore his commitment to advancing life sciences. We are privileged to have Dr. Opstelten guide our scientific endeavors.

Dr. Opstelten: “Batavia’s commitment to move the field of vaccines and virotherapy forward, with a string focus on science and quality is unsurpassed. I am delighted to chair the scientific advisory board with seasoned experts in this arena to support their mission.”

Dr. Dirk-Jan Opstelten - Chairman Scientific Advisory Board Batavia Biosciences

Low-cost viral vector manufacturing

High-throughput screening for viral vectors

Viral vector manufacturing

Maximizing protein expression